Syndecan-2	NN
is	VBZ
a	DT
novel	JJ
target	NN
of	IN
insulin-like	JJ
growth	NN
factor	NN
binding	NN
protein-3	NN
and	CC
is	VBZ
over-expressed	JJ
in	IN
fibrosis	NN
.	.

Extracellular	JJ
matrix	NN
deposition	NN
and	CC
tissue	NN
scarring	NN
characterize	VBP
the	DT
process	NN
of	IN
fibrosis	NN
.	.

Transforming-growth-factor-beta	NN
(	(
TGFb	NN
)	)
and	CC
Insulin-like-growth-factor-binding-protein-3	NN
(	(
IGFBP-3	NN
)	)
have	VBP
been	VBN
implicated	VBN
in	IN
the	DT
pathogenesis	NN
of	IN
fibrosis	NN
in	IN
various	JJ
tissues	NNS
by	IN
inducing	VBG
mesenchymal	JJ
cell	NN
proliferation	NN
and	CC
extracellular	JJ
matrix	NN
deposition	NN
.	.

We	PRP
identified	VBD
Syndecan-2	NN
(	(
SDC2	NN
)	)
as	IN
a	DT
gene	NN
induced	VBN
by	IN
TGFb	NN
in	IN
an	DT
IGFBP-3-dependent	JJ
manner	NN
.	.

TGFb	NN
induction	NN
of	IN
SDC2	NN
mRNA	NN
and	CC
protein	NN
required	VBD
IGFBP-3	NN
.	.

IGFBP-3	NN
independently	RB
induced	VBD
production	NN
of	IN
SDC2	NN
in	IN
primary	JJ
fibroblasts	NNS
.	.

Using	VBG
an	DT
ex-vivo	NN
model	NN
of	IN
human	JJ
skin	NN
in	IN
organ	NN
culture	NN
expressing	VBG
IGFBP-3	NN
,	,
we	PRP
demonstrate	VBP
that	IN
IGFBP-3	NN
induces	VBZ
SDC2	NN
ex	FW
vivo	FW
in	IN
human	JJ
tissue	NN
.	.

We	PRP
also	RB
identified	VBD
Mitogen-activated	JJ
protein	NN
kinase-interacting	NN
kinase	NN
(	(
Mknk2	NN
)	)
as	IN
a	DT
gene	NN
induced	VBN
by	IN
IGFBP-3	NN
.	.

IGFBP-3	NN
triggered	VBD
Mknk2	NN
phosphorylation	NN
resulting	VBG
in	IN
its	PRP$
activation	NN
.	.

Mknk2	NN
independently	RB
induced	VBD
SDC2	NN
in	IN
human	JJ
skin	NN
.	.

Since	IN
IGFBP-3	NN
is	VBZ
over-expressed	JJ
in	IN
fibrotic	JJ
tissues	NNS
,	,
we	PRP
examined	VBD
SDC2	NN
levels	NNS
in	IN
skin	NN
and	CC
lung	NN
tissues	NNS
of	IN
patients	NNS
with	IN
systemic	JJ
sclerosis	NN
(	(
SSc	NN
)	)
and	CC
lung	NN
tissues	NNS
of	IN
patients	NNS
with	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

SDC2	NN
levels	NNS
were	VBD
increased	VBN
in	IN
fibrotic	JJ
dermal	JJ
and	CC
lung	NN
tissues	NNS
of	IN
patients	NNS
with	IN
SSc	NN
and	CC
in	IN
lung	NN
tissues	NNS
of	IN
patients	NNS
with	IN
IPF	NN
.	.

This	DT
is	VBZ
the	DT
first	JJ
report	NN
describing	VBG
elevated	JJ
levels	NNS
of	IN
SDC2	NN
in	IN
fibrosis	NN
.	.

Increased	VBN
SDC2	NN
expression	NN
is	VBZ
due	JJ
,	,
at	IN
least	JJS
in	IN
part	NN
,	,
to	TO
the	DT
activity	NN
of	IN
two	CD
pro-fibrotic	JJ
factors	NNS
,	,
TGFb	NN
and	CC
IGFBP-3	NN
.	.

